Cohance Lifesciences Limited (BOM:543064)

Cohance Lifesciences Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	886.7	472.31	648.03	445.64	71.82
Short-Term Investments	1,917	-	-	-	-
Trading Asset Securities	-	7,739	4,189	4,812	1,806
Cash & Short-Term Investments	2,804	8,211	4,837	5,258	1,878
Cash Growth	-65.85%	69.75%	-8.00%	180.01%	343.20%
Accounts Receivable	2,844	1,337	1,109	2,364	1,024
Other Receivables	100	562.28	665.92	480.04	516.22
Receivables	2,948	1,907	1,777	2,846	1,542
Inventory	1,666	2,326	3,306	3,000	2,127
Prepaid Expenses	-	49.21	86.28	64	43.97
Other Current Assets	1,468	138.34	103.79	111.67	56.72
Total Current Assets	8,886	12,632	10,110	11,279	5,648
Property, Plant & Equipment	12,500	7,868	7,662	5,620	5,349
Long-Term Investments	1,450	1,306	1,171	1,171	3,612
Goodwill	6,551	602.58	602.58	-	-
Other Intangible Assets	638.9	16.67	19.32	22.36	25.91
Long-Term Deferred Tax Assets	5.5	-	-	-	-
Other Long-Term Assets	240.8	116.09	91.64	203.02	109.54
Total Assets	30,318	22,541	19,657	18,296	14,745
Accounts Payable	802.1	423.57	700.92	1,059	829.31
Accrued Expenses	178.7	151.87	128.17	266	198.03
Short-Term Debt	-	385.75	445.98	-	641.89
Current Portion of Long-Term Debt	718.9	-	200	671.33	414.48
Current Portion of Leases	314.5	51.86	4.79	10.91	10.68
Current Income Taxes Payable	11	-	2.94	36.42	-
Current Unearned Revenue	-	6.89	8.08	-	-
Other Current Liabilities	1,627	49.02	96.79	59.27	103.08
Total Current Liabilities	3,652	1,069	1,588	2,103	2,197
Long-Term Debt	62.4	-	45.64	284.4	355.91
Long-Term Leases	1,695	212.36	7	4.63	7.39
Long-Term Deferred Tax Liabilities	909.8	647.91	582.35	543.15	309.33
Other Long-Term Liabilities	5,592	97.68	82.95	77.85	44.99
Total Liabilities	11,911	2,034	2,306	3,024	2,937
Common Stock	254.6	254.57	254.57	254.57	254.57
Additional Paid-In Capital	-	1,096	1,096	1,096	1,096
Retained Earnings	-	18,894	15,894	13,820	10,308
Comprehensive Income & Other	16,711	262.39	107.17	101.65	150.09
Total Common Equity	16,966	20,507	17,352	15,272	11,808
Minority Interest	1,441	-	-	-	-
Shareholders' Equity	18,406	20,507	17,352	15,272	11,808
Total Liabilities & Equity	30,318	22,541	19,657	18,296	14,745
Total Debt	2,791	649.96	703.41	971.27	1,430
Net Cash (Debt)	13.4	7,561	4,134	4,287	447.4
Net Cash Growth	-99.82%	82.91%	-3.56%	858.10%	-
Net Cash Per Share	0.05	29.70	16.24	16.84	1.76
Filing Date Shares Outstanding	254.61	254.56	254.56	254.56	254.56
Total Common Shares Outstanding	254.61	254.56	254.56	254.56	254.56
Working Capital	5,234	11,563	8,523	9,176	3,450
Book Value Per Share	66.64	80.56	68.16	59.99	46.39
Tangible Book Value	9,776	19,887	16,730	15,249	11,782
Tangible Book Value Per Share	38.40	78.12	65.72	59.90	46.28
Land	-	150.46	150.46	150.46	150.46
Buildings	-	2,209	2,200	1,813	1,411
Machinery	-	5,607	5,410	4,750	3,909
Construction In Progress	-	1,790	1,651	299.94	961.49
Leasehold Improvements	-	42.6	-	-	-

Updated Feb 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.